&w=3840&q=100)
Merck's potential cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.
The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade.
Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes.
Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol.
BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies.
The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said.
However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial.
Merck has not given the details on LDL-C reduction for enlicitide.
The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin.
Shares of Merck were up 2% in premarket trading.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 days ago
- Mint
The S&P 500 is eyeing a new record. Why the bond market still holds power.
The S&P 500 is not far from marking a new record close, yet investors may not be feeling very enthusiastic. The index appears rich: Investors are still paying a nearly three-year-high multiple for anticipated future profits, making stocks particularly vulnerable to negative surprises. U.S. economic growth has been sufficient, but tariffs, along with geopolitical conflicts in the Middle East and elsewhere, raise the specters of higher prices and slower growth—which could spur stagflation. Analysts are worried that such a scenario could negatively hit company profits as consumers spend less. The bond market, meanwhile, has gotten lost in the list of market worries. Investors should pay attention—they may still pack a punch. True, bonds haven't done much in June. The yield on the 10-year Treasury note has oscillated in a 25-basis-points range over the last 20 trading days, the smallest range over a one-month period since fall 2024, wrote BMO Capital Markets strategists Vail Hartman and Ian Lyngen in a note. If the yield on the 10-year pushes much higher, stock prices are expected to take a hit: When yields are elevated, investors often move money to bonds, which are less-risky and offer better returns. But it doesn't need to always play out that way. The stock market's reaction to bond yields will be driven by the underlying reasons for the rise, not just the absolute yield numbers. Higher yields due to better-than-expected economic growth are good news for companies' profits, and in turn, their stocks. However, higher yields due to more term premium—which measures the extra yield investors demand to stash away money for a decade, rather than just repeatedly investing in short-term securities—signal economic uncertainty and can hurt stocks. Term premium is now adding 70 basis points onto the yield for the 10-year. Term premium is driven by myriad factors, including market supply and demand for bonds, central bank policies, and uncertainty about government regulations. The relative impact of each of these factors is hard to measure and can shift over time. Term premiums are not observable and cannot be traded. People have models for rough bearings, but there's inherent uncertainty around the estimates, wrote Benson Durham, Piper Sandler's head of global policy and asset allocation, in a Wednesday note. Wars, for example, increase the supply of U.S. Treasuries—but investors will find the supply less threatening if there's demand for these notes. If the demand from investors looks weak, the term premium will move higher at some point to reflect this mismatch in supply and demand. 'There's certainly a threshold that we think of with regard to how big those negative supply shocks have to be to for these things to get priced immediately, which I think would be a serious bear market in equities, and would cause a genuine rise in term premium," Freya Beamish, Chief economist at TS Lombard, told Barron's Uncertain economic policies that change too quickly can also raise term premium—especially if more slow-moving investors like pension funds and insurers, who plug in money on longer-dated bonds, retreat. 'My point is this—if you want an answer as to how [5% yield on the 10-year Treasuries] might affect the S&P 500, much more background is required, even if a story, Durham wrote. 'And no one can ever be too sure." Write to Karishma Vanjani at
&w=3840&q=100)
Business Standard
5 days ago
- Business Standard
AI + Leadership: Lessons from Merck's Global Head
AI meets leadership in this episode of Manager's Mantra with Dr. Harsha Gurulingappa, Global Head of AI at Merck. Learn how tech is reshaping healthcare and what it takes to lead in the AI era.
Economic Times
6 days ago
- Economic Times
Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create
Stir things up Rollout of the ₹5,000-cr Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme signals a shift in how India approaches the sector's growth. This initiative, expected to begin disbursals by the end of 2025, could attract ₹17,000 cr in additional R&D investment. For an industry that has long been associated with generic manufacturing, this represents a paradigm shift towards innovation-led pharma world is approaching a 'patent cliff', and for Indian firms, it represents an unprecedented opportunity: 24 mega-selling drugs with combined annual sales exceeding $250 bn will lose patent protection by 2030. This means blockbuster medicines like Humira for rheumatoid arthritis, Keytruda for cancer treatment, Stelara for psoriasis, and Symbicort for asthma will soon be open for generic manufacturing. When these patents expire, drug prices fall by at least 50%. For a country where out-of-pocket (OoP) healthcare expenses are high, this holds immense significance alongside its commercial potential. Capturing these opportunities won't be easy. Indian firms will face tough competition from generics and must match the original drug standards. Success will hinge on investment in bioequivalence studies, regulatory compliance and resilient supply chains. Indian pharma companies are eyeing these opportunities. Zydus, Sun Pharma, and Bharat Serums and Vaccines (now part of Mankind Pharma) have invested in establishing world-class R&D centres, focusing on developing new chemical entities. The younger generation of scientists and entrepreneurs, bringing fresh perspectives, is accelerating the transition from a generic-focused industry to one that balances both generic excellence and innovative drug discovery. MNCs are also rethinking their view of the Indian market: Novartis, Novo Nordisk and Eli Lilly have chosen to out-license their brands to Indian firms rather than directly market them here. This trend reflects both the growing capabilities of domestic firms and the unique challenges of serving India's diverse and price-sensitive market. These partnerships benefit all. International companies can maintain a presence in India without the complexities of direct operations, while Indian firms gain access to established brands and molecules, leveraging deep market understanding and extensive distribution networks. However, building these relationships requires investment in compliance systems, quality infrastructure, and continuous capability upgrades to meet the exacting standards of international positives in the sector include: Exemption of 36 life-saving drugs from basic customs duty will benefit companies bringing in innovative medicines. Drugs like AstraZeneca's Selumetinib, Pfizer's Lorlatinib, Novartis' Ribociclib, and GSK's Mepolizumab will now be more affordable. Additionally, six more life-saving medicines have been added to the concessional 5% duty slab, primarily targeting cancer, rare diseases and other chronic conditions. The health budget has risen to over ₹95,000 cr for FY26, up 9.46%. More than a numbers game, it's about building a healthcare ecosystem fit for our vast population. 15,479 Jan Aushadhi Kendras provide generic medicines at prices up to 80% lower than branded equivalents. A heart medicine that once cost ₹500 is available for ₹100, bringing essential treatments within reach of ordinary citizens. Yet, ensuring consistent quality and maintaining reliable supply chains remain a challenge. Extension of PM Ayushman Yojana to people above 70 years creates a virtuous cycle - more people seeking treatment drives demand for medicines, which, in turn, encourages pharma companies to invest in better products and wider distribution. Development of healthcare infra in tier-2 and tier-3 cities is also helping. However, attracting and retaining qualified medical professionals in these locations remains a hurdle, requiring innovative approaches to compensation, career development and quality-of-life considerations. Again, the market for pharma products will, then, be able to expand. A 'nutraceutical revolution' is underway. With the market expected to grow from $4 bn in 2020 to $18 bn by December, nutraceuticals represent a significant growth avenue for companies willing to invest in quality and innovation. The convergence of multiple factors - patent opportunities, GoI support, infrastructure development and changing consumer behaviour - is creating unprecedented opportunities for the sector. Companies that embrace innovation, while maintaining traditional strengths in affordable healthcare delivery, will thrive. The writer is CEO, Mankind Pharma (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Second only to L&T, but controversies may weaken this infra powerhouse's growth story Looking for quick buck in unlisted shares? Better think twice! How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Stock Radar: Supreme Industries stock down by about 30%! Breakout from rounding bottom formation suggests bulls are catching up Two Trades for Today: A large-cap auto major for 6.7% gain, a mid-cap auto stock for almost 7% rise After a gap of 4 years, are HDFC, Axis, Kotak banks ready for re-rating? 5 bank stocks with upside potential of up to 35% For medium- to long-term investors with moderate risk appetite: 6 large-cap stocks with an upside potential of up to 40%
